ILG-F Fusion Protein

About ILGEN

ILGEN is a private, pre-revenue biotech developing a proprietary platform for rapidly generating high-affinity, fully human antibodies and fusion proteins. Its core technology, protected by a US patent, aims to significantly shorten antibody discovery timelines to under six months compared to traditional methods. The company's pipeline features an anti-LAG-3 immune checkpoint inhibitor for oncology and a fusion protein, ILG-F, for vasculogenic erectile dysfunction, both derived from its human tissue-based approach. ILGEN has presented preclinical data at major conferences like ESMO and AACR but remains at an early, non-clinical stage.

Therapeutic Areas